ArriVent Says Cancer Drug Candidate Firmonertinib Misses Primary Endpoint in Phase 3 Trial; Shares Fall Pre-Bell

MT newswire2026/10/06 12:50

08:50 AM EDT, 10/06/2026 (MT Newswires) -- ArriVent BioPharma's (AVBP) phase 3 Furvent trial of firmonertinib did not achieve its primary progression-free survival goal in previously untreated patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, the company said Tuesday. According to the study, media progression-free survival was 11 months for the 240mg firmonertinib dose; 8.4 months for 160mg, and 9.5 months for the control arm, while confirmed response rates were 60%, 35% and 33%, respectively. The safety profile was consistent with prior studies, with no new safety signals. Grade 3 or higher adverse events occurred in 52% of patients on the 240mg dose, 53% on the 160mg dose, and 55% in the control arm, the company said. Shares of ArriVent fell more than 56% in recent premarket activity Tuesday. Price: 12.50, Change: -15.96, Percent Change: -56.08

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.